Tissue plasminogen activator-based nanothrombolysis for ischemic stroke.

ABSTRACT:

Introduction

Thrombolysis with intravenous tissue plasminogen activator (tPA) is the only FDA approved treatment for patients with acute ischemic stroke, but its use is limited by narrow therapeutic window, selective efficacy, and hemorrhagic complication. In the past two decades, extensive efforts have been undertaken to extend its therapeutic time window and explore alternative thrombolytic agents, but both show little progress. Nanotechnology has emerged as a promising strategy to improve the efficacy and safety of tPA.

Areas covered

We reviewed the biology, thrombolytic mechanism, and pleiotropic functions of tPA in the brain and discussed current applications of various nanocarriers intended for the delivery of tPA for treatment of ischemic stroke. Current challenges an

SUBMITTER: Liu S 

PROVIDER: S-EPMC5780255 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature